Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 9/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.38 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78773 | 0.94 | SLC9A1 (0.46) | SLC9A1POLBMAPK1ATMKEAP1 | |
| SCHEMBL30378712 | 0.94 | SLC9A1 (0.46) | SLC9A1POLBMAPK1ATMKEAP1 | |
| SCHEMBL1462681 | 0.92 | SLC9A1 (0.44) | SLC9A1POLBMAPK1ATMKEAP1 | |
| Bromide SCHEMBL5514455 | 0.92 | SLC9A1 (0.44) | SLC9A1POLBMAPK1ATMKEAP1 | |
| SCHEMBL5090298 | 0.92 | SLC9A1 (0.44) | SLC9A1POLBMAPK1ATMKEAP1 | |
| SCHEMBL44479 | 0.91 | SLC9A1 (0.41) | SLC9A1POLBMAPK1ATMKEAP1 | |
| SCHEMBL1941412 | 0.91 | SLC9A1 (0.41) | SLC9A1POLBMAPK1ATMKEAP1 | |
| SCHEMBL2824611 | 0.91 | SLC9A1 (0.41) | SLC9A1POLBMAPK1ATMKEAP1 | |
| Fluoride SCHEMBL4594157 | 0.91 | SLC9A1 (0.43) | SLC9A1POLBMAPK1ATMKEAP1 | |
| Fluoride Ion SCHEMBL619776 | 0.91 | SLC9A1 (0.43) | SLC9A1POLBMAPK1ATMKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20240400552-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2024-12-05 | — | — | US | disclosed |
| US-20230405016-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2023-12-21 | — | — | US | disclosed |
| US-11622968-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20220340556-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220296605-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2022-09-22 | — | — | US | disclosed |
| US-11034690-B2 | Heterocyclic modulators of lipid synthesis | Saginiet Biosciences Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3190108-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20190308969-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190269694-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2019-09-05 | — | — | US | disclosed |
| US-6472435-B1 | ANTITUMOR ANTIPROLIFERATION AGENT FORMED BY AMIDATION OF CARBOXY ACID WITH AROMATIC AMINE COMPOUND | ASTRAZENECA AB (SE) | 2002-10-29 | — | — | US | disclosed |
| US-6346633-B1 | TERT-AMINOPHENYLESTER OF ACID | ASTRAZENECA AB (SE) | 2002-02-12 | — | — | US | disclosed |
| EP-1155011-A1 | DI- AND TRIPEPTIDE NITRILE DERIVATIVES AS INHIBITORS OF CATHEPSIN L AND CATHEPSIN S | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| EP-1155010-A1 | ACETAMIDO ACETONITRILE DERIVATIVES AS INHIBITORS OF CATHEPSIN L AND/OR CATHEPSIN S | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| EP-1064257-A1 | ANTI-TUMOUR AGENTS | AstraZeneca AB (SE) | 2001-01-03 | — | — | EP | disclosed |
| EP-1064253-A1 | ANTI-TUMOUR AGENTS | AstraZeneca AB (SE) | 2001-01-03 | — | — | EP | disclosed |
| WO-2000049008-A1 | DI- AND TRIPEPTIDE NITRILE DERIVATIVES AS INHIBITORS OF CATHEPSIN L AND CATHEPSIN S | ASTRAZENECA AB (SE) | 2000-08-24 | — | — | WO | disclosed |
| WO-2000049007-A1 | ACETAMIDO ACETONITRILE DERIVATIVES AS INHIBITORS OF CATHEPSIN L AND/OR CATHEPSIN S | ASTRAZENECA AB (SE) | 2000-08-24 | — | — | WO | disclosed |
| WO-1999048857-A1 | ANTI-TUMOUR AGENTS | ASTRAZENECA AB (SE) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999048860-A1 | ANTI-TUMOUR AGENTS | ASTRAZENECA AB (SE) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340556-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | SLC9A1 4533/4885POLB 2667/4885MAPK1 2563/4885 |
| US-20230405016-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | SLC9A1 4540/4885POLB 3095/4885MAPK1 2090/4885 |
| US-20240400552-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | SLC9A1 4533/4885POLB 2667/4885MAPK1 2563/4885 |
| US-11034690-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, SCD | SLC9A1 4532/4885POLB 2887/4885MAPK1 2223/4885 |
| US-20220296605-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, SCD | SLC9A1 4532/4885POLB 2887/4885MAPK1 2223/4885 |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, FADS2 | SLC9A1 676/4885POLB 3427/4885MAPK1 911/4885 |
| US-20190308969-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, SCD | SLC9A1 4499/4885POLB 2946/4885MAPK1 2065/4885 |
| US-20190269694-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, SCD | SLC9A1 4532/4885POLB 2887/4885MAPK1 2223/4885 |
| US-11622968-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, SCD | SLC9A1 4532/4885POLB 2887/4885MAPK1 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.